Group 1 - The Hong Kong Innovative Drug ETF (513120) increased by 1.03% on February 9, with a trading volume of 3.646 billion yuan [1] - The fund's shares decreased by 36.5 million, bringing the total shares to 20.21 billion, with an increase of 982 million shares over the last 20 trading days [1] - The latest net asset value of the fund is 25.98 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the CSI Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has returned 28.54%, while the return over the past month is -5.38% [1]

Group 1 - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 0.95% on February 5, with a trading volume of 4.106 billion yuan [1] - The fund's shares increased by 517 million, bringing the total shares to 20.217 billion, with a total increase of 970 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 25.534 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has achieved a return of 26.29%, while the return over the past month is -0.84% [1]

Group 1 - The Hong Kong Innovative Drug ETF (513120) increased by 1.28% on February 4, with a trading volume of 4.119 billion yuan [1] - The fund's shares rose by 12.4 million, bringing the total shares to 19.699 billion, with an increase of 42.9 million shares over the last 20 trading days [1] - The latest net asset value of the fund is 24.746 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (calculated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has achieved a return of 25.61%, with a return of 4.54% over the past month [1]

Core Insights - The biotechnology industry is rapidly developing and is a key direction for global technological revolution and industrial upgrading, with innovative drugs being a core engine aligned with the "Healthy China" strategy [1] - By 2026, the Hong Kong stock market's biotechnology sector is expected to see a significant increase in merger and acquisition activities, with Goldman Sachs predicting record-high global pharmaceutical and biotechnology M&A volumes [1] - The Chinese biotechnology sector is currently driven by a combination of policy benefits, capital support, and technological breakthroughs, with a shift in regulatory focus from cost control to encouraging quality innovation [1][2] Industry Trends - There is a persistent demand for the diagnosis and treatment of diseases such as cancer and cardiovascular conditions, supported by increased consumer payment capacity and rising healthcare expenditures, providing substantial growth opportunities for the industry [2] - The industry is transitioning from "broad innovation" to "differentiated innovation and international development," with a significant number of innovative drugs expected to be approved in China by 2025 [2] - In 2025, 76 innovative drugs are projected to be approved in China, with over 80% being domestic innovations, and a record total of over $130 billion in licensing transactions for innovative drugs [2] Investment Opportunities - The Hang Seng Biotechnology Index (HSBIO.HI) highlights the investment value of high-purity and scarce biotechnology companies, focusing on leading firms in the sector with a low overlap with traditional pharmaceuticals [3] - The index includes 30 leading biotechnology companies listed in Hong Kong, with a significant portion of its weight concentrated in the top ten stocks, including WuXi Biologics and BeiGene [3] - The Guangfa Hang Seng Biotechnology ETF, launched to facilitate efficient investment in core biotechnology assets, offers T+0 trading and low fees, positioning it as an attractive option for investors looking to capitalize on the sector's growth [3][4]

Group 1 - The cross-border ETF market has seen significant inflows, with over 13.8 billion yuan in net purchases since the beginning of the year, bringing the total market size to nearly 978.8 billion yuan, approaching the 1 trillion yuan mark [1] - There are currently 25 cross-border ETF products with a scale exceeding 10 billion yuan, highlighting the growing interest in this investment category [1] - GF Fund has a leading position in the cross-border ETF market, managing 11 cross-border ETFs, of which 5 have surpassed 10 billion yuan in size, accounting for 45% of the total number of such products in the market [1] Group 2 - GF Fund's flagship products include the Nasdaq ETF (159941), which has a scale exceeding 30 billion yuan and has demonstrated a strong annualized return of over 17% since its inception [2] - The Hong Kong Stock Connect Non-Bank Financial ETF (513750) is unique in tracking the non-bank financial sector in Hong Kong, with over 68% exposure to the insurance industry [2] - The Hong Kong Stock Connect Innovative Drug ETF (513120) is the largest of its kind, having increased by over 66% since 2025, showcasing the high concentration of innovative drug assets [2] Group 3 - GF Fund has been systematically developing its index business since 2008, establishing a comprehensive product line across multiple markets, including A-shares, Hong Kong stocks, US stocks, and commodities [3] - The company has received a five-star rating for its index fund management capabilities, based on a comprehensive assessment of tracking ability, excess return capability, and overall costs [3]

Group 1 - The cross-border ETF market has seen significant inflows, with over 13.8 billion yuan in net purchases since the beginning of the year, bringing the total market size to nearly 978.8 billion yuan, approaching the 1 trillion yuan mark [1] - There are currently 25 cross-border ETF products with a scale exceeding 10 billion yuan, with the Hong Kong Stock Connect Technology ETF (159262) recently reaching a scale of 10.117 billion yuan, making it a new addition to the billion-yuan category [1] - GF Fund has a leading position in the cross-border ETF market, managing 11 cross-border ETFs, of which 5 have surpassed 10 billion yuan in scale, accounting for 45% of the total number of billion-yuan cross-border ETFs in the market [1][2] Group 2 - GF Fund's five billion-yuan products cover core assets and high-growth sectors across different markets, including the Nasdaq ETF (159941), which has a scale exceeding 30 billion yuan and an annualized return of over 17% since inception [2] - The Hong Kong Stock Connect Non-Bank Financial ETF (513750) is the only tool tracking the Hong Kong Stock Connect non-bank financial theme index, with over 68% exposure to the insurance industry [2] - The Hong Kong Stock Connect Innovative Drug ETF (513120) is the largest in its category, having increased by over 66% since 2025, while the Hong Kong Stock Connect Technology ETF (159262) and the Hang Seng Technology ETF (513380) focus on AI technology leaders and classic technology assets, respectively [2] Group 3 - GF Fund has been systematically developing its index business since 2008, establishing a comprehensive product line across A-shares, Hong Kong stocks, US stocks, and commodities, making it one of the most complete providers of index products [3] - The company's index investment management capabilities have been recognized by authoritative institutions, earning a five-star rating in the index fund management capability from the Ji'an Jinxin Fund Evaluation Center [3]

Core Insights - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 1.55% on December 30, with a trading volume of 2.959 billion yuan [1] - The fund's shares increased by 95 million to a total of 19.475 billion shares, with a notable increase of 780 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 23.736 billion yuan [1] Performance Metrics - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the CSI Hong Kong Innovative Drug Index (denominated in RMB) [1] - Managed by Guangfa Fund Management Co., the fund has achieved a return of 21.87% since its inception on July 1, 2022 [1] - Over the past month, the fund has recorded a return of -9.90% [1]

Core Insights - The article emphasizes the collective intelligence of investors, highlighting that the "Top Ten Core Asset Portfolio" launched by the company in 2019 has achieved a cumulative return of 274.61% by December 15, significantly outperforming the Shanghai and Shenzhen 300 Index and the Hang Seng Index [1] - In 2023, the company launched another portfolio called "Global Vision: Betting on China," which has recorded a 15.16% increase in 2024, outperforming the Wind All A Index by 5.16% [1] - As of December 26, 2025, the "Global Vision: Betting on China" portfolio has achieved a 29.72% increase, surpassing the Shanghai and Shenzhen 300 Index by 11.36 percentage points [1] ETF Performance Summary - The A500 ETF Fund (512050.SH) recorded a 25.58% increase in 2025 [2] - The ChiNext 50 ETF (159949.SZ) saw a remarkable increase of 60.67% [2] - The Hong Kong Innovation Drug ETF (513120) led the performance with a 71.86% increase [2] - The Semiconductor Theme ETF (588200.SH) experienced a decline of 59.15% [2] - The Internet Theme ETF (159792.SZ) increased by 24.033% [2] - The H-share ETF (510900.SH) rose by 21.58% [2] - The Consumption ETF (159928.SZ) decreased by 2.08% [2] - The Broker ETF (512000.SH) increased by 5.00% [2] - The S&P 500 ETF (513500.SH) recorded a 13.83% increase [2] Industry Highlights - The pharmaceutical sector has transformed from one of the worst-performing sectors to one of the strongest, with innovative drug companies frequently achieving record-breaking sales [3] - The total transaction volume for innovative drug license-out deals is expected to exceed $100 billion, accounting for nearly half of the global pharmaceutical business development transaction volume [4] - The Hong Kong Innovation Drug ETF (513120) tracks the China Hong Kong Innovation Drug Index, focusing on high-quality biotech companies in the Hong Kong market [4] - The ETF has a current scale of 24.1 billion yuan, with an average daily trading volume exceeding 5.3 billion yuan, making it the largest and most liquid thematic index fund in the market [4] - The ChiNext 50 ETF (159949) has also performed well, with a year-to-date increase of 59.86% and a significant increase of 129.61% since the "924" period [5][7] Market Trends - The ChiNext 50 Index employs a unique "liquidity-first, scale-second" strategy, selecting the 50 largest and most liquid stocks from the ChiNext 100, representing the core strengths of the ChiNext market [9] - The ETF's performance benefits from the dual advantages of leading stocks and sector rotation, particularly in the information technology and new energy sectors [9] - Looking ahead to 2026, the market is expected to benefit from continued overseas liquidity easing and domestic policies aimed at expanding domestic demand, which may improve the corporate profit environment [10]

Core Insights - The Hong Kong Innovative Drug ETF (513120) increased by 1.99% on December 4, with a trading volume of 4.785 billion yuan [1] - The fund's shares rose by 23 million to a total of 1.8832 billion shares, with an increase of 541 million shares over the past 20 trading days [1] - The latest net asset value of the fund is 25.204 billion yuan [1] - The fund's performance benchmark is the return of the CSI Hong Kong Innovative Drug Index (in RMB), managed by Guangfa Fund Management Co., Ltd. [1] - Since its inception on July 1, 2022, the fund has achieved a return of 33.83%, with a return of 0.35% over the past month [1]

Group 1 - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 0.44% on December 1, with a trading volume of 3.824 billion yuan [1] - The fund's shares increased by 4 million, bringing the total shares to 18.690 billion, with a notable increase of 1.290 billion shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 25.209 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its inception on July 1, 2022, the fund has achieved a return of 34.87%, while the return over the past month is -0.55% [1]